Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Buy at StockNews.com

StockNews.com cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research note released on Saturday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $32.07 on Friday. The company has a market capitalization of $1.79 billion, a P/E ratio of 29.97 and a beta of 0.83. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The company’s 50-day moving average is $36.70 and its 200 day moving average is $35.27.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 over the last three months. 9.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. Pacer Advisors Inc. increased its position in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares during the period. Woodline Partners LP increased its position in shares of Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock worth $15,326,000 after purchasing an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock worth $10,581,000 after purchasing an additional 208,552 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $6,847,000. Finally, Great Lakes Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $6,131,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.